Four 5,6-dimethylxanthone-4-acetic acid (D) and pyranoxanthone (P) hybrids (D-P-n) were design-synthesized based on multi-target-addressed strategy. D-P-4 was confirmed as the most active agent against HepG-2 cell line growth with an IC₅₀ of 0.216 ± 0.031 μM. Apoptosis analysis indicated different contributions of early/late apoptosis/necrosis to cell death for both monomers, the combination (D + P in 1:1 mol ratio) and D-P-4. They all arrested more cells on S phase. Western Blot implied that D-P-4 regulated p53/MDM2 to a better healthy state. Moreover, it improved Bax/Bcl-2 signaling pathway to increase cancer cell apoptosis. In all cases studied, D-P-4 showed the best activity and synergistic effect. All the evidences support that D-P-4 is a better anti-cancer therapy with multi-target functions.

基于多目标寻址策略设计合成了4个5,6-二甲基黄酮-4-乙酸（D）和吡喃酮（P）杂化物（DPn）。证实DP-4是对抗HepG-2细胞系生长的最具活性的药物，IC ₅₀为0.216±0.031μM。凋亡分析表明，两种单体（D  +  P 1：1摩尔比）和DP-4两种单体的早期/晚期凋亡/坏死对细胞死亡的不同贡献。他们都在S期逮捕了更多的细胞。Western Blot暗示DP-4调节p53 / MDM2使其达到更好的健康状态。此外，它改善了Bax / Bcl-2信号传导途径，以增加癌细胞的凋亡。在所有研究的案例中，DP-4表现出最佳的活性和协同作用。所有证据都支持DP-4是一种具有多目标功能的更好的抗癌疗法。